PR Newswire (Tue, 9:30AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,525 people get MYL articles and Market Currents by email alert.
Get email alerts on MYL »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
PR Newswire (Fri, 7:30AM)
-
-
-
-
PR Newswire (Wed, 11:40AM)
-
-
PR Newswire (May 2, 2013)
-
PR Newswire (Apr 30, 2013)
-
-
PR Newswire (Apr 22, 2013)
-
-
-
PR Newswire (Apr 9, 2013)
-
-
PR Newswire (Apr 3, 2013)
-
PR Newswire (Mar 18, 2013)
To learn more about Seeking Alpha Pro, click here.
-
-
-
Why You Should Hold On To MylanDieter Plas • Thu, Feb 7 -
Obamacare Just Part Of The Mylan StoryDana Blankenhorn • Fri, Nov 9, 2012 -
Mylan: Profit From The Generics Boom With This PharmaCris Frangold • Thu, Nov 8, 2012 -
Generics Will Drive Mylan Higher By 2013Cris Frangold • Fri, Aug 31, 2012
-
-
Mylan: Execution, Valuation Discount Suggest Further Upside AheadAlex Shadunsky • Tue, May 22, 2012 -
-
-
-
-
Mylan: Earnings PreviewZacks Investment Research • Mon, Jul 25, 2011 -
-
Mylan: Earnings PreviewZacks Investment Research • Wed, Apr 27, 2011
-
Diagonal Spread in Mylan Has Bearish BiasoptionMONSTER • Tue, Mar 23, 2010 -
Mylan Strengthens Portfolio With Generic Diabetes DrugsZacks Investment Research • Wed, Mar 17, 2010
-
Earnings Preview: MylanTheflyonthewall • Wed, Oct 28, 2009 -
Earnings Preview: MylanTheflyonthewall • Wed, Jul 29, 2009
-
Mylan: Showing Up DoubtersAllen Phatimer • Mon, Feb 23, 2009
-
-
-
-
-
-
-
-
Billionaire John Paulson's Top Stock PicksInsider Monkey • Thu, Feb 21
-
-
-
-
-
-
-
-
-
-
-
-
VIX - Options Volatility Sonar: Friday RecapErick McKitterick • Fri, Oct 26, 2012
-
Mylan Management Discusses Q3 2012 Results - Earnings Call TranscriptThu, Oct 25, 2012
-
Mylan Management Discusses Q2 2012 Results - Earnings Call TranscriptThu, Jul 26, 2012
-
Mylan's CEO Discusses Q1 2012 Results - Earnings Call TranscriptThu, Apr 26, 2012
-
Mylan, Inc. - Analyst/Investor DayTue, Feb 21, 2012
-
Mylan's CEO Discusses Q3 2011 Results - Earnings Call TranscriptWed, Oct 26, 2011
-
Mylan's CEO Discusses Q2 2011 Results - Earnings Call TranscriptWed, Jul 27, 2011
-
Mylan's CEO Discusses Q4 2010 Results - Earnings Call TranscriptThu, Feb 24, 2011
-
Mylan Q3 2010 Earnings Call TranscriptTue, Oct 26, 2010
-
Mylan CEO Discusses Q3 2010 Results - Earnings Call TranscriptTue, Oct 26, 2010
-
Mylan Laboratories Inc. Q1 2010 Earnings Call TranscriptThu, Apr 29, 2010
-
Mylan Inc. Q4 2009 Earnings Call TranscriptMon, Mar 1, 2010
-
Mylan Inc. Q2 2009 Earnings Call TranscriptThu, Jul 30, 2009
-
Mylan Inc. Q1 2009 Earnings Call TranscriptFri, May 1, 2009
-
Mylan Inc. Q3 2008 Earnings Call TranscriptThu, Oct 30, 2008
-
Mylan Inc Q2 2008 Earnings Call TranscriptWed, Aug 6, 2008
-
Mylan Q1 2008 Earnings Call TranscriptMon, May 19, 2008
-
at CNBC.com (Mon, 8:00AM)
-
at Fox Business (Mon, 7:23AM)
-
PR Newswire (Fri, 7:30AM)
-
at CNBC.com (Thu, 7:33AM)
-
PR Newswire (Wed, 11:40AM)
-
at CNBC.com (Wed, 7:42AM)
-
PR Newswire (May 2, 2013)
-
PR Newswire (Apr 30, 2013)
-
at CNBC.com (Apr 26, 2013)
-
PR Newswire (Apr 22, 2013)
-
PR Newswire (Apr 9, 2013)
-
PR Newswire (Apr 3, 2013)
-
at CNBC.com (Mar 25, 2013)
-
PR Newswire (Mar 18, 2013)
-
PR Newswire (Mar 13, 2013)
-
PR Newswire (Mar 4, 2013)
-
at MarketWatch.com (Feb 28, 2013)
-
PR Newswire (Feb 27, 2013)
MYL vs. ETF Alternatives
Company Description
Long considered a leader in the United States (“U.S.”) generic pharmaceutical market, Mylan has grown into a worldwide pharmaceutical leader and is currently the third largest generic and specialty pharmaceutical company in the world, in terms of revenues. This evolution has taken place through... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, May 14, 1:29 PM Actavis (ACT +1.2%) spikes on reports that the company recently turned away a $15B bid from Mylan (MYL +0.1%). Comment! [Healthcare, On the Move, M&A]
- Thursday, May 2, 5:18 PM More on Mylan (MYL): Q1 misses on top line estimates as net earnings fell 17% Y/Y amid acquisition-related expenses and other items. The generic-drug maker reported modest growth for the quarter, thanks to its specialty business which posted revenue growth of 22% to $226.6M. Generics revenue was flat at $1.41B, as growth in its EMEA segment and its Asia Pacific business was offset by declines in North America. Gross margin rose slightly to 42.5% from 42.3%. Shares -3.4% AH. Comment! [Healthcare, Earnings, On the Move]
- Tuesday, April 30, 1:44 PM The FDA approves Raptor Pharmaceuticals' (RPTP +11%) Procysbi, a delayed-release version of Mylan's (MYL -0.1%) Cystagon. The drugs treat nephropathic cystinosis. RPTP could see revenues of $77M in 2015 from the drug, Bloomberg says. Comment! [Healthcare, On the Move]
- Wednesday, February 27, 5:18 PM Mylan (MYL) acquires Agila Specialties, a developer, manufacturer and marketer of high-quality generic injectable products, from Strides Arcolab for $1.6B in cash. The acquisition significantly expands MYL's global injectables platform and will provide entry into new high-growth geographic markets. The acquisition is expected to close in Q4 of 2013 should be immediately accretive to earnings. Shares +1.8% AH. 1 Comment [Healthcare, M&A, On the Move]
- Wednesday, February 27, 5:02 PM Mylan Labs (MYL): Q4 EPS of $0.65 beats by $0.02. Revenue of $1.72B (+13% Y/Y) misses by $0.01B. Shares -2% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
- Wednesday, November 21, 2012, 12:51 PM Mylan (MYL +1.5%) says it's board has approved a buyback of up to $500M in common stock. The news follows an earlier report that Moody's had upgraded the company's credit ratings to Baa3 from Ba1 and that S&P raised its credit rating to BBB- from BB+. Comment! [Healthcare, On the Move]
- Thursday, August 2, 2012, 11:13 AM Gilead Sciences (GILD +8.3%) says it plans to partner with Mylan (MYL -1.5%), Ranbaxy Laboratories (RBXZF.PK) and Strides Arcolab to promote access to generic versions of Gilead's HIV medicine containing Emtricitabine in developing countries. The drug is marketed by GILD under the brand names Emtriva and Truvada. WHO guidelines recommend the drug as preferred components of first and second line HIV therapy. Comment! [Healthcare, On the Move, Global & FX]
- Thursday, July 26, 2012, 8:39 AM Mylan Labs (MYL): Q2 EPS of $0.6 beats by $0.05. Revenue of $1.69B (+7.4% Y/Y) beats by $0.03B. Shares +2.6% premarket. (PR) Comment! [Earnings, Healthcare, On the Move]
- Wednesday, July 18, 2012, 11:43 AM Somaxon (SOMX +83%) soars this morning - after initially surging over 150% in pre-open trading - on the back of yesterday's announcement of its litigation settlement over Silenor with Mylan (MYL +0.8%) and Par Pharmaceuticals. The company added that it sees higher Q2 net sales for Silenor, now seeing revenue of approximately $2.8M to $2.9M, up from reported sales of $2.7M in Q1. Comment! [Healthcare, On the Move]
- Sunday, June 24, 2012, 9:07 AM Teva Pharmaceutical (TEVA) is +10.5% in Tel Aviv following the favorable ruling on its Copaxone patent in a case against Momenta (MNTA) and Mylan (MYL). While industry watchers had assumed Teva would prevail, with ~35% of its EPS at risk, a hearty sigh of relief isn't surprising. 11 Comments [Top Stories, On the Move, Healthcare]
- Thursday, May 10, 2012, 2:24 PM Mylan (MYL +1.9%) gets a bump higher after the generic-drug maker raised its FY12 earnings outlook earlier today. It now expects to earn between $2.45 - $2.55 per share. Street consensus is for an EPS of $2.42. The company also outlined plans to repurchase up to $500M in stock in a bid to increase shareholder value. Comment! [Healthcare, On the Move]
- Friday, March 2, 2012, 3:58 PM Mylan (MYL -2.1%) trades lower thanks to an unfavorable ruling in its patent infringement suit against Sunovion Pharmaceuticals related to its Brovana respiratory drug. A New York court granted a motion related to one of Sunovion's patent defenses, and also the company's request to limit damages. Mylan says it's appealing the ruling, and will continue to pursue an injunction. Comment! [Healthcare, On the Move]
- Tuesday, February 14, 2012, 3:32 PM Mylan (MYL +1%) gains on an upgrade to Buy from at Goldman, citing improved earnings visibility and an underestimated margin expansion led by the company's EpiPen product mix shift. Comment! [On the Move, Healthcare]
- Tuesday, December 20, 2011, 12:50 PM Mylan (MYL +3.5%) says one of its subsidiaries has received approval for three antiretroviral therapies used to treat HIV/AIDS under the World Health Organization's Prequalification of Medicines Program. Comment! [Healthcare, On the Move]
- Tuesday, December 13, 2011, 1:26 PM Warner Chilcott (WCRX -0.9%) says a federal appeals court has vacated a lower court's ruling that would have prevented Mylan (MYL +0.6%) from releasing a generic version of its Doryx acne drug until pending patent litigation was decided. The company says it will still vigorously defend its Doryx patent and intends to seek a new restraining order from the district court. Comment! [Healthcare, On the Move, Global & FX]
- Monday, November 28, 2011, 3:04 PM Mylan (MYL +4.1%) jumps after receiving final FDA approval of its Abbreviated New Drug Application for its chemoprotective agent Dexrazoxane for injection, a generic version of Pharmacia & Upjohn's Zinecard. Comment! [Healthcare, On the Move]
-
- View all 0 replies
-
StockViews
Canaccord downgrade $MYL to HOLD. "Catalysts behind us and upside limited". View 2013 as a "transition year" - View all 0 replies
-
Jim Van Meerten
$MYL - 100% Barchart technical buy signals - 8 new highs and up 5.25% in the last month - Relative Strength Index 65.70% - View all 0 replies
-
Jim Van Meerten
$MYL - 96% Barchart technical buy signal - 9 new hgihs and up 6.94% in the last month - Relative Strength Index 67.89% - View all 0 replies
-
Jim Van Meerten
MYL - 96% Barchart technical buy signal - 6 new highs and up 4.48% in the last month - Relative Strength Index 63.0% - View all 0 replies
-
- View all 0 replies
-
Jim Van Meerten
MYL - 96% Barchart technical buy signal - 5 new highs and up 2.89% in the last month - Relative Strength Index 63.03% - View all 0 replies
-
- View all 0 replies
-
John Motyka
I sold MYL prematurely in light of this weeks' action. I continue to Hold my position in MAKO...JDM - View all 0 replies
-
John Motyka
IMUC and LGND moving against down market. Both feature similar paradigm shifting healthcare treatment modalities. Sold MYL for LT gain. - View all 0 replies
LATEST REPLIES